| Literature DB >> 29552391 |
Riccardo Rizzo1, Maria Alvaro2, Norbert Danz3, Lucia Napione2,4, Emiliano Descrovi1, Stefan Schmieder5, Alberto Sinibaldi6, Subinoy Rana7, Rona Chandrawati7,8, Peter Munzert3, Thomas Schubert9, Emmanuel Maillart10, Aleksei Anopchenko6,11, Paola Rivolo1, Alessandro Mascioletti12, Erik Förster3,13, Frank Sonntag5, Molly M Stevens7, Federico Bussolino2,14, Francesco Michelotti6,15.
Abstract
Quantitative detection of angiogenic biomarkers provides a powerful tool to diagnose cancers in early stages and to follow its progression during therapy. Conventional tests require trained personnel, dedicated laboratory equipment and are generally time-consuming. Herein, we propose our developed biosensing platform as a useful tool for a rapid determination of Angiopoietin-2 biomarker directly from patient plasma within 30 minutes, without any sample preparation or dilution. Bloch surface waves supported by one dimensional photonic crystal are exploited to enhance and redirect the fluorescence arising from a sandwich immunoassay that involves Angiopoietin-2. The sensing units consist of disposable and low-cost plastic biochips coated with the photonic crystal. The biosensing platform is demonstrated to detect Angiopoietin-2 in plasma samples at the clinically relevant concentration of 6 ng/mL, with an estimated limit of detection of approximately 1 ng/mL. This is the first Bloch surface wave based assay capable of detecting relevant concentrations of an angiogenic factor in plasma samples. The results obtained by the developed biosensing platform are in close agreement with enzyme-linked immunosorbent assays, demonstrating a good accuracy, and their repeatability showed acceptable relative variations.Entities:
Keywords: (240.6690) Surface waves; (280.1415) Biological sensing and sensors; (280.4788) Optical sensing and sensors
Year: 2018 PMID: 29552391 PMCID: PMC5854056 DOI: 10.1364/BOE.9.000529
Source DB: PubMed Journal: Biomed Opt Express ISSN: 2156-7085 Impact factor: 3.732